Audit: QRS - Methylphenidate for Health & Longevity
Audit conducted on 20/09/2026 20:00 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol values (5 mg 2–3× daily → 20–60 mg; 18 mg → 54–72 mg; 30–60 minutes; 4–6 weeks; 3–4 hours per dose), all nine biomarker targets, the cadence sentence, all benefit/risk items and all gate items trace to ER lines 443–453, 498, 526–545, 410–419 and the Expected Benefits / Potential Risks headings. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No established numeric target” (marker_8_target) and “No established target; track change from own baseline” (marker_9_target) mirror ER lines 535–536; “Pregnancy (guidance stays cautious)” mirrors ER line 419. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Tier placement matches the ER exactly; the conflicted items stay in the same Low tier the ER assigns them, and the pregnancy gate keeps the ER’s cautious qualifier rather than dropping or hardening it. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No content from ER Benefit-Modifying Factors (lines 241–251) or Risk-Modifying Factors (lines 365–375) appears anywhere in the QRS; gates draw solely on Key Interactions & Contraindications. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PubMed ID, citation, expert name, NCT identifier or brand name. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind in the QRS body. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Terse, declarative, evidence-first register throughout, matching the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Numeric targets and tiers carry the data; the At-A-Glance opens with the established effect before the costs. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Descriptive noun phrases (“Osmotic-release capsules each morning, raised in 18 mg steps”) rather than instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives, no “should”, “must”, “recommend” or “advise” anywhere in the body. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Every cell states what is done or observed, not what the reader ought to do. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns present. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are condition names with no shorter equivalent (pheochromocytoma, priapism, Raynaud’s phenomenon); explanatory cells use plain wording (“Iron limits the enzyme that makes dopamine”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items and tier lists are short phrases; the At-A-Glance is 59 words. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by scan for second-person forms; none found. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Home blood-pressure logging, ferritin and thyroid targets and qualitative self-tracking all presume a proactive adult. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nine-marker panel, staged cadence and six qualitative trackers presuppose effortful follow-through. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Optimal functional ranges (ferritin 50–100 ng/mL, TSH 0.5–2.0 mIU/L) are tighter than conventional reference ranges, matching the ER’s stated framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The At-A-Glance separates the diagnosed from the non-diagnosed adult case, the distinction that matters for this readership. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No “pill”, “shot”, “by mouth” or equivalent; formulation is named formally (“Immediate-release”, “Osmotic-release capsules”, “Extended-release”). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings match the template byte-for-byte (QRS lines 440, 477, 519, 539, 555, 581, 600, 604–606, 719 and the four tier labels in both tier cards). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Programmatic set comparison against core/qrs/QRS.html: no template variable missing; the only extras are the expected marker_1..9_* and qualitative_item_1..6 expansions of the marker_#_* / qualitative_item_# row templates. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans (website="evidence_review", website="audit", website="full_review") are unchanged at QRS lines 423, 426 and 434. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section used by the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Immediate-release titration”, “Extended-release once-daily dosing”, “Best time of day”, “Time to effect” and “Half-life and coverage” are the ER’s bold labels verbatim (ER lines 443, 445, 451, 453, 498); every Key Interaction item leads with the ER’s bold label. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels carry the ER wording; “Time to optimal dose” names the second half of the ER’s own Time to effect bullet, which the sheet must split because 11.1 requires three distinct time sets. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the QRS; tiers are rendered with <strong> labels and the CSS palette only. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every item is compressed to a short phrase and all explanatory clauses, mechanisms and effect sizes are stripped; item counts are fixed by the ER via 9.2, 14.2 and 15.2 and cannot be reduced further. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | QRS lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the preamble text on line 2 sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed entirely in an HTML comment; no element on the sheet repeats any metadata value. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon; all other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: methylphenidate_2026-0920-1614_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0920-1941. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk: methylphenidate_2026-0920-1614_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; only the colon-bearing duration value is quoted. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Methylphenidate for Health & Longevity - Quick Reference Sheet, matching ER frontmatter canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Methylphenidate for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/20/2026, the correct MM/DD/YYYY rendering of 2026-0920-1941. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415–428) is the template block with only the three variables substituted. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses ER lines 569–571: mechanism, the diagnosed-population effect, the non-diagnosed effect, and the cost profile. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words by word count. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the four sentences maps to a distinct clause of the ER Conclusion (lines 569 and 571). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “alertness and reward chemicals” replaces dopamine/noradrenaline and “people meeting diagnostic criteria” replaces the ADHD label. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No SMD, odds ratio, hazard ratio or confidence interval appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items trace to ER lines 380, 384 and 412–419. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | The eight bullets of “Populations who should avoid Methylphenidate” plus the day-of-surgery anaesthetic contraindication from ER line 384 (“Caution to absolute contraindication on the day of surgery”). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Nine <li> elements at QRS lines 542–550. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Definitional glosses and the pregnancy citation are stripped; no dash-trailing clause survives in any item. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “within the past 14 days”, “within 90 days”, “at or above 180/110 mmHg”, “without supervised dispensing” and “(halothane, sevoflurane, desflurane)” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify such populations, so the constraint holds. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All fourteen items trace to ER lines 382–408. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Every non-contraindicated ER interaction bullet is present; the MAOI bullet and the anaesthetic clause are correctly excluded because they appear in the Contraindications gate. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Fourteen <li> elements at QRS lines 558–571. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s explanatory glosses (“compounds mimicking adrenaline —”, “an early antidepressant generation —”, “the common modern antidepressant class —”, “drugs that block dopamine signalling”) and all mitigation sentences are stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drugs are retained for every bullet that carries them (sympathomimetics, midodrine/droxidopa, tricyclics, SSRIs, stimulant supplements, blood-pressure-lowering supplements); lists are trimmed, never dropped. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated and the ER lists fifteen interaction bullets, so the constraint holds. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action sets come from ER Therapeutic Protocol lines 443, 445 and 451. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Immediate-release titration, extended-release once-daily dosing and timing of day are the three execution decisions the ER’s remaining bullets (genetics, sex, age, payer incentives) all modify rather than replace. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER mentions thirteen actionable protocol aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine cells carry ER-derived content; none is empty or placeholder. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Onset (30–60 minutes), time to optimal dose (4–6 weeks) and per-dose duration/coverage are the only time-to-effect quantities the ER supplies (lines 453 and 498). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered from the fastest, most directly experienced effect through titration to the coverage window that governs the dosing schedule. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine cells carry ER-derived content; the half-life sub-cell combines ER lines 453 and 130. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All fourteen items correspond one-to-one with the ER’s #### benefit headings at lines 152–236. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated (QRS lines 521–532) with the ER’s 3 / 5 / 4 / 2 tier distribution. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading reduced to a noun phrase; no Magnitude figure, mechanism sentence or evidence note carries over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers have items in the ER, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All sixteen items correspond one-to-one with the ER’s #### risk headings at lines 262–360. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated (QRS lines 583–594) with the ER’s 6 / 2 / 7 / 1 tier distribution. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading reduced to a noun phrase; no frequency, relative risk or mechanism carries over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear anywhere in the four risk spans. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers have items in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence both derive from ER Monitoring Protocol & Defining Success, lines 524–536. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER table rows are present in order: resting pulse, blood pressure, body weight, sleep latency and total sleep, ferritin, TSH, fasting glucose, electrocardiogram, full blood count — with targets matching the ER’s optimal functional ranges. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS line 713 reproduces the ER’s cadence sentence from line 524, including the one-week-after-dose-change rule and the annual blood panel. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER’s “Qualitative markers tracked alongside the laboratory panel” list, lines 540–545. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are present verbatim at QRS lines 722–737. |
Issues 20/09/2026 20:00
Pass rate 100.00%. No issues found.
Issues 20/09/2026 19:57
- 1.2 — Electrocardiogram target drops ER hedge: [marker_8_target] (QRS line 692) reads “Sinus rhythm; corrected QT below 450 ms in men, 460 ms in women”, omitting the ER’s “No established numeric target” qualifier (ER line 535), while [marker_9_target] preserves the equivalent hedge for the full blood count.
Fixes 20/09/2026 19:57
- 1.2 — Electrocardiogram target hedge restored: [marker_8_target] changed from “Sinus rhythm; corrected QT below 450 ms in men, 460 ms in women” to “No established numeric target; sinus rhythm, corrected QT below 450 ms in men, 460 ms in women”, matching the ER’s own qualifier.
Issues 20/09/2026 19:52
- 1.1 — Coverage hours not ER-supported: [time_3_sub] (QRS line 511) claims “modified-release designs stretch coverage to 10–12 hours”, but the ER’s general statement is “extended-release designs stretch coverage to 8–12 hours” (ER line 130); the 10–12 hour figure applies in the ER only to osmotic-release capsules (ER line 445).
Fixes 20/09/2026 19:52
- 1.1 — Coverage hours aligned to ER: [time_3_sub] changed from “modified-release designs stretch coverage to 10–12 hours” to “extended-release designs stretch coverage to 8–12 hours”, matching the ER’s general statement at ER line 130.
Issues 20/09/2026 19:47
- 12.3 / 12.4 — “(conflicted)” qualifier in benefits: [benefits_low] at line 528 preserves three added parentheticals “(conflicted)”; section 12’s preamble states the tier already encodes evidence strength, so such qualifiers must be stripped.
- 13.3 / 13.4 — “(conflicted)” qualifier in risks: [risks_low] at line 590 preserves three added parentheticals “(conflicted)”, which section 13 requires to be stripped for the same reason.
- 4.3 — Invented time-to-effect label: [time_2_label] at line 494 is “Optimal dose”, a label found nowhere in the ER, and paired with the value “4–6 weeks” it misreads as a dose rather than the time the ER says titration to the optimal dose takes.
Fixes 20/09/2026 19:47
- 12.3 / 12.4 — “(conflicted)” stripped from benefits: Removed the three “(conflicted)” parentheticals from [benefits_low], leaving “Reduced cancer-related fatigue; … reduced use in stimulant use disorder; reduced depressive symptoms as add-on treatment”.
- 13.3 / 13.4 — “(conflicted)” stripped from risks: Removed the three “(conflicted)” parentheticals from [risks_low], leaving the cardiovascular, growth-suppression and tic items as bare tiered descriptors.
- 4.3 — Time-to-effect label corrected: Changed [time_2_label] from “Optimal dose” to “Time to optimal dose” so the label matches its value “4–6 weeks” and the ER’s statement that finding the optimal dose takes four to six weeks.